{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:59:31Z","timestamp":1789523971660,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.atherosclerosis.2011.02.010","type":"journal-article","created":{"date-parts":[[2011,2,18]],"date-time":"2011-02-18T04:44:55Z","timestamp":1298004295000},"page":"266-278","source":"Crossref","is-referenced-by-count":40,"title":["Effects of ezetimibe on atherosclerosis in preclinical models"],"prefix":"10.1016","volume":"215","author":[{"suffix":"Jr.","given":"Harry R.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Neff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35025203","article-title":"Atherosclerosis","volume":"407","author":"Lusis","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0010","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis \u2013 update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri2675","article-title":"Macrophage death and defective inflammation resolution in atherosclerosis","volume":"10","author":"Tabas","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00001573-200109000-00006","article-title":"The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes","volume":"16","author":"Kolodgie","year":"2001","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0025","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/CIRCULATIONAHA.107.753152","article-title":"Evidence mandating earlier and more aggressive treatment of hypercholesterolemia","volume":"118","author":"Steinberg","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0035","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0040","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1072-7515(02)01275-9","article-title":"Overall mortality in the program on the surgical control of the hyperlipidemias","volume":"195","author":"Buchwald","year":"2002","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0050","unstructured":"Zetia (ezetimibe) tablets [package insert]. North Wales, PA, USA: Merck\/Schering-Plough Pharmaceuticals; 2009."},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0055","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14779072.6.4.447","article-title":"Ezetimibe: cholesterol lowering and beyond","volume":"6","author":"Bays","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0060","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","article-title":"Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes","volume":"156","author":"Cannon","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/jm030283g","article-title":"The discovery of ezetimibe: a view from outside the receptor","volume":"47","author":"Clader","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0070","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0075","doi-asserted-by":"crossref","first-page":"33586","DOI":"10.1074\/jbc.M405817200","article-title":"Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis","volume":"279","author":"Davis","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0080","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.0500269102","article-title":"The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)","volume":"102","author":"Garcia-Calvo","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/clpt.2009.209","article-title":"Transporters as drug targets: discovery and development of NPC1L1 inhibitors","volume":"87","author":"Betters","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0090","doi-asserted-by":"crossref","first-page":"11140","DOI":"10.1073\/pnas.0800936105","article-title":"Extracellular loop C of NPC1L1 is important for binding to ezetimibe","volume":"105","author":"Weinglass","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0095","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.cmet.2008.04.001","article-title":"The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1","volume":"7","author":"Ge","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0100","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.bbalip.2007.03.002","article-title":"Class B type I scavenger receptor is responsible for the high affinity cholesterol binding activity of intestinal brush border membrane vesicles","volume":"1771","author":"Labonte","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0105","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1194\/jlr.M900036-JLR200","article-title":"Influence of class B scavenger receptors on cholesterol flux across the brush border membrane and intestinal absorption","volume":"50","author":"Nguyen","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0110","first-page":"e85","article-title":"Intestinal cholesterol uptake in SR-BI and Niemann-Pick Like 1 knockout mice","volume":"27","author":"Lally","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0115","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1124\/dmd.30.4.430","article-title":"Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects","volume":"30","author":"Patrick","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0120","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions","volume":"44","author":"Kosoglou","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0125","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.tox.2009.01.017","article-title":"An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach","volume":"258","author":"Halleck","year":"2009","journal-title":"Toxicology"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0130","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.genom.1.1.507","article-title":"Far more than a lipid transport protein","volume":"1","author":"Mahley","year":"2000","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0135","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0092-8674(92)90362-G","article-title":"Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells","volume":"71","author":"Plump","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0140","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/hq1201.100260","article-title":"Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice","volume":"21","author":"Davis","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0145","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.ATV.0000257627.40486.46","article-title":"Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE\u2212\/\u2212 mice","volume":"27","author":"Davis","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0150","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2008.05.026","article-title":"Vascular protective effects of ezetimibe in ApoE-deficient mice","volume":"203","author":"Nakagami","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0155","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jacc.2007.09.074","article-title":"Vascular effects of diet supplementation with plant sterols","volume":"51","author":"Weingartner","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0160","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s10554-009-9487-5","article-title":"High resolution magnetic resonance imaging in atherosclerotic mice treated with ezetimibe","volume":"25","author":"Dietrich","year":"2009","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0165","unstructured":"Tang H, Chang CH, Suresch D, et al. In vivo volumetric MRI in drug discovery: a preclinical case study of the ezetimibe therapeutic efficacy on atherosclerosis in the thoracic ascending arterial tree in apoE\u2212\/\u2212 mice. International Society of Magnetic Resonance in Medicine 2009, 17th scientific meeting and exhibition. Available from: http:\/\/www.miracd.com\/ismrm2009\/Proceedings\/files\/00030.pdf [accessed 18.01.11]."},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0170","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2310\/7290.2008.0009","article-title":"Monitoring therapeutical intervention with ezetimibe using targeted near-infrared fluorescence imaging in experimental atherosclerosis","volume":"7","author":"Graf","year":"2008","journal-title":"Mol Imaging"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0175","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/hh0302.104462","article-title":"Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice","volume":"90","author":"Braun","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0180","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.atherosclerosis.2007.10.012","article-title":"Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI\/apoE double knockout mice","volume":"198","author":"Braun","year":"2008","journal-title":"Atherosclerosis"},{"issue":"18; Suppl. S","key":"10.1016\/j.atherosclerosis.2011.02.010_bib0185","first-page":"186","article-title":"Ezetimibe reduces plasma cholesterol and inhibits the development of atherosclerosis in apo E knockout mice with and without LDL receptors","volume":"102","author":"Davis","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0190","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1194\/jlr.M400475-JLR200","article-title":"Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption","volume":"46","author":"Repa","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0195","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1194\/jlr.M600353-JLR200","article-title":"Hepatic ABCG5\/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited","volume":"48","author":"Basso","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0200","doi-asserted-by":"crossref","first-page":"22913","DOI":"10.1074\/jbc.M402838200","article-title":"Hepatic ABCG5 and ABCG8 overexpression increases hepatobiliary sterol transport but does not alter aortic atherosclerosis in transgenic mice","volume":"279","author":"Wu","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0205","first-page":"252A","article-title":"The cholesterol absorption inhibitor SCH58235 and lovastatin synergistically lower plasma cholesterol and inhibit the development of atherosclerosis","volume":"35","author":"Davis","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0210","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/j.1476-5381.2008.00091.x","article-title":"Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect","volume":"156","author":"Gomez-Garre","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2011.02.010_bib0215","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S1567-5688(09)70463-5","article-title":"Cholesterol lowering inhibits crystal formation with associated plaque disruption, thrombosis and inflammation","volume":"10","author":"Patel","year":"2009","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0220","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11239-006-7861-x","article-title":"Arterial wall cholesterol content is a predictor of development and severity of arterial thrombosis","volume":"22","author":"Ma","year":"2006","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0225","doi-asserted-by":"crossref","first-page":"E1183","DOI":"10.1152\/ajpendo.90899.2008","article-title":"Intestinal lipid absorption","volume":"296","author":"Iqbal","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0230","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0014-2999(01)00825-1","article-title":"The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys","volume":"415","author":"Van Heek","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0235","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1194\/jlr.M600439-JLR200","article-title":"The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin","volume":"48","author":"Telford","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0240","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/01.ATV.0000216750.09611.ec","article-title":"Effect of ezetimibe on the in vivo kinetics of ApoB-48 and ApoB-100 in men with primary hypercholesterolemia","volume":"26","author":"Tremblay","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0245","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2796.2007.01898.x","article-title":"Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins","volume":"263","author":"Tall","year":"2008","journal-title":"J Intern Med"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0250","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1161\/ATVBAHA.108.165803","article-title":"Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages","volume":"28","author":"Sehayek","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0255","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1752-8062.2009.00098.x","article-title":"Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol","volume":"2","author":"Briand","year":"2009","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0260","first-page":"E65","article-title":"Ezetimibe enhances tissue cholesterol efflux and whole body reverse cholesterol transport (RCT) in normal rats","volume":"28","author":"Turner","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0265","first-page":"E196","article-title":"Ezetimibe treatment stimulates transport of plasma cholesterol into fecal neutral sterols in hyperlipidemic humans","volume":"30","author":"Turner","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0270","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0275","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.jacc.2008.11.002","article-title":"Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness","volume":"52","author":"Stein","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0280","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","article-title":"Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia","volume":"356","author":"Kastelein","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0285","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2004.09.015","article-title":"Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia","volume":"95","author":"van Wissen","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0290","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/jama.299.14.1678","article-title":"Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial","volume":"299","author":"Howard","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0295","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.jacc.2008.10.031","article-title":"Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial","volume":"52","author":"Fleg","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0300","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0305","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0310","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.amjcard.2010.01.363","article-title":"Observed and predicted reduction of ischemic cardiovascular events in the simvastatin and ezetimibe in aortic stenosis trial","volume":"105","author":"Holme","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0315","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1046\/j.1523-1755.63.s84.4.x","article-title":"Study of Heart and Renal Protection (SHARP)","author":"Baigent","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0320","unstructured":"SHARP Collaborative Group. Study of Heart and Renal Protection (SHARP): a randomized trial of cholesterol-lowering therapy among patients with chronic kidney disease. Denver, Colorado: American Society of Nephrology; 2010 [Abstract]. Presentation slides available at: http:\/\/www.ctsu.ox.ac.uk\/\u223csharp\/slides.htm [accessed 18.01.11]."},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0325","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0330","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2011.02.010_bib0335","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915011001663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915011001663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T12:51:27Z","timestamp":1559998287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915011001663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0021915011001663"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.02.010","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}